HALO:NGS-Halozyme Therapeutics Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 64.42

Change

+1.22 (+1.93)%

Market Cap

USD 1.64B

Volume

1.29M

Analyst Target

USD 33.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Halozyme Therapeutics Inc is a biopharmaceutical company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-11.11 (-0.95%)

USD 130.01B
VRTX Vertex Pharmaceuticals Inc

+6.72 (+1.40%)

USD 123.52B
ALNY Alnylam Pharmaceuticals Inc

+3.54 (+1.35%)

USD 33.60B
ARGX argenx NV ADR

+2.24 (+0.42%)

USD 32.41B
MRNA Moderna Inc

-1.40 (-2.01%)

USD 28.23B
BGNE BeiGene Ltd

+2.22 (+1.13%)

USD 20.54B
BMRN Biomarin Pharmaceutical Inc

+0.52 (+0.62%)

USD 17.44B
RPRX Royalty Pharma Plc

+0.17 (+0.62%)

USD 17.14B
UTHR United Therapeutics Corporatio..

-1.99 (-0.58%)

USD 15.72B
PCVX Vaxcyte Inc

+1.87 (+1.64%)

USD 14.27B

ETFs Containing HALO

ROYL:AU BetaShares Global Royalti.. 4.05 % 0.00 %

+0.17 (+2.48%)

N/A
FBT:LSE First Trust Global Funds .. 3.57 % 0.00 %

+18.60 (+2.48%)

USD 7.71M
FBTU:LSE First Trust Global Funds .. 3.57 % 0.00 %

+0.36 (+2.48%)

USD 7.71M
BIOT:SW L&G Pharma Breakthrough U.. 3.12 % 0.00 %

N/A

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 3.09 % 0.00 %

+0.03 (+2.48%)

USD 0.02B
HLTH:AU VanEck Global Healthcare .. 2.71 % 0.00 %

N/A

USD 0.06B
EQUL IndexIQ ETF Trust - IQ En.. 1.51 % 0.00 %

+0.32 (+2.48%)

USD 7.19M
FSCC Federated Hermes ETF Trus.. 1.43 % 0.00 %

+0.60 (+2.48%)

N/A
AGED:SW iShares Ageing Population.. 0.57 % 0.00 %

+0.08 (+2.48%)

N/A
RTWO:LSE L&G Russell 2000 US Small.. 0.47 % 0.00 %

+2.22 (+2.48%)

USD 0.13B
RTWP:LSE Legal & General UCITS ETF.. 0.47 % 0.00 %

+143.50 (+2.48%)

USD 0.13B
ETLZ:XETRA L&G Russell 2000 US Small.. 0.47 % 0.00 %

+1.67 (+2.48%)

USD 0.09B
BFOR Barron's 400 ETF 0.36 % 0.65 %

+1.10 (+2.48%)

USD 0.14B
RSSL Global X Funds 0.30 % 0.00 %

+2.07 (+2.48%)

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+2.51 (+2.48%)

N/A
FNX First Trust Mid Cap Core .. 0.00 % 0.62 %

+2.06 (+2.48%)

USD 1.19B
FNY First Trust Mid Cap Growt.. 0.00 % 0.70 %

+1.16 (+2.48%)

USD 0.35B
GSC Goldman Sachs ETF Trust 0.00 % 1.25 %

+0.98 (+2.48%)

N/A
HDG ProShares Hedge Replicati.. 0.00 % 0.95 %

+0.20 (+2.48%)

USD 0.03B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+1.20 (+2.48%)

N/A
SMCP AlphaMark Actively Manage.. 0.00 % 0.90 %

+0.83 (+2.48%)

USD 0.03B
PSC Principal U.S. Small-Cap .. 0.00 % 0.38 %

+1.05 (+2.48%)

USD 0.62B
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

+0.11 (+2.48%)

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

+5.75 (+2.48%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+5.85 (+2.48%)

N/A
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

+3.34 (+2.48%)

USD 0.41B
UWM ProShares Ultra Russell20.. 0.00 % 0.95 %

+1.90 (+2.48%)

USD 0.25B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

-0.09 (2.48%)

N/A
IBBJ 0.00 % 0.00 %

N/A

N/A
2B77:F iShares Ageing Population.. 0.00 % 0.00 %

+0.06 (+2.48%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 74.30% 88% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.30% 88% B+ 93% A
Trailing 12 Months  
Capital Gain 49.88% 81% B- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.88% 81% B- 88% B+
Trailing 5 Years  
Capital Gain 289.95% 92% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 289.95% 92% A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 28.98% 77% C+ 84% B
Dividend Return 28.98% 77% C+ 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.53% 60% D- 34% F
Risk Adjusted Return 56.23% 96% N/A 82% B
Market Capitalization 1.64B 97% N/A 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.50 28% 39%
Price/Book Ratio 38.07 5% 3%
Price / Cash Flow Ratio 20.60 4% 15%
Price/Free Cash Flow Ratio 15.76 4% 22%
Management Effectiveness  
Return on Equity 153.16% 100% 99%
Return on Invested Capital 16.62% 88% 85%
Return on Assets 13.38% 99% 97%
Debt to Equity Ratio 1,788.91% 1% 0%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.